ZA200509508B - Composition for improving cognition and memory - Google Patents

Composition for improving cognition and memory

Info

Publication number
ZA200509508B
ZA200509508B ZA200509508A ZA200509508A ZA200509508B ZA 200509508 B ZA200509508 B ZA 200509508B ZA 200509508 A ZA200509508 A ZA 200509508A ZA 200509508 A ZA200509508 A ZA 200509508A ZA 200509508 B ZA200509508 B ZA 200509508B
Authority
ZA
South Africa
Prior art keywords
memory
composition
improving cognition
cognition
improving
Prior art date
Application number
ZA200509508A
Other languages
English (en)
Inventor
Laudon Moshe
Zisapel Nava
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of ZA200509508B publication Critical patent/ZA200509508B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200509508A 2003-04-29 2006-11-24 Composition for improving cognition and memory ZA200509508B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment

Publications (1)

Publication Number Publication Date
ZA200509508B true ZA200509508B (en) 2006-11-29

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509508A ZA200509508B (en) 2003-04-29 2006-11-24 Composition for improving cognition and memory

Country Status (29)

Country Link
US (2) US8859593B2 (ru)
EP (1) EP1620058B1 (ru)
JP (2) JP4981440B2 (ru)
KR (1) KR101136885B1 (ru)
CN (1) CN1787820B (ru)
AR (1) AR048370A1 (ru)
AT (1) ATE539746T1 (ru)
BR (1) BRPI0409935A (ru)
CA (1) CA2521182C (ru)
CL (1) CL2004000877A1 (ru)
CY (1) CY1112689T1 (ru)
DK (1) DK1620058T3 (ru)
EA (1) EA008768B1 (ru)
ES (1) ES2380364T3 (ru)
HK (1) HK1087635A1 (ru)
IL (1) IL155666A (ru)
IS (1) IS8090A (ru)
MX (1) MXPA05011590A (ru)
NO (1) NO333015B1 (ru)
NZ (1) NZ542724A (ru)
PE (1) PE20050144A1 (ru)
PL (1) PL1620058T3 (ru)
PT (1) PT1620058E (ru)
SI (1) SI1620058T1 (ru)
TW (1) TWI340037B (ru)
UA (1) UA87980C2 (ru)
UY (1) UY28296A1 (ru)
WO (1) WO2004096118A2 (ru)
ZA (1) ZA200509508B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
JP2010523714A (ja) 2007-04-12 2010-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 虚血／再灌流保護組成物および使用法
KR102593047B1 (ko) 2012-01-26 2023-10-24 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2893542C (en) * 2012-12-18 2022-07-19 Vanda Pharmaceuticals Inc. Use of tasimelteon in the treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10744122B2 (en) * 2015-02-04 2020-08-18 Soeur Josefa Menendez Transdermal therapeutic system containing valentonin and use thereof as a medicament
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) * 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4680172A (en) 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
ATE71287T1 (de) 1986-06-13 1992-01-15 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
PT100973A (pt) * 1991-10-18 1994-06-30 Alza Corp Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
JPH07506720A (ja) * 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
EP0565296B1 (en) * 1992-04-07 1996-08-07 Neurim Pharmaceuticals (1991) Limited Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
CA2166869A1 (en) * 1993-07-09 1995-01-19 Ooi Wong Method and device for providing nicotine replacement therapy transdermally/transbuccally
JPH09512006A (ja) 1994-04-13 1997-12-02 チバ−ガイギー アクチェンゲゼルシャフト 時間的に調節された薬物供給システム
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
BR9607169A (pt) 1995-02-01 1997-11-11 Neurim Pharma 1991 Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
WO1997042941A2 (en) 1996-05-13 1997-11-20 Novartis Consumer Health S.A. Buccal delivery system
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
ATE254618T1 (de) * 1997-05-30 2003-12-15 Neurosearch As Spiro chinuclidin-derivate, ihre herstellung und verwendung
AU3364499A (en) * 1998-03-25 1999-10-18 New York University Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO2000012045A2 (en) * 1998-08-26 2000-03-09 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
PT1150661E (pt) 1999-02-05 2004-02-27 Cipla Ltd Produto para pulverizacao para aplicacao topica
US6353051B1 (en) * 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
EE200200379A (et) 2000-01-05 2003-10-15 Neurim Pharmaceuticals (1991) Ltd. Meetod ja preparaat antihüpertensiivsete ainete suhtes resistentsuse ja sellega seotud haigusseisundite raviks
EP1311272B1 (en) * 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
CN101301275A (zh) 2001-03-26 2008-11-12 史密丝克莱恩比彻姆公司 含烟碱的口服剂量形式的制备方法
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
DE60105820D1 (de) * 2001-10-22 2004-10-28 Pera Ivo E Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit
US7113651B2 (en) * 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
CY1112689T1 (el) 2016-02-10
CA2521182A1 (en) 2004-11-11
TWI340037B (en) 2011-04-11
ATE539746T1 (de) 2012-01-15
MXPA05011590A (es) 2006-03-08
CA2521182C (en) 2011-05-31
CN1787820B (zh) 2010-05-05
CN1787820A (zh) 2006-06-14
EA008768B1 (ru) 2007-08-31
PE20050144A1 (es) 2005-05-12
PL1620058T3 (pl) 2012-07-31
BRPI0409935A (pt) 2006-04-25
ES2380364T3 (es) 2012-05-11
NO20055531L (no) 2005-11-23
WO2004096118A2 (en) 2004-11-11
EP1620058A4 (en) 2006-07-26
JP2006525317A (ja) 2006-11-09
WO2004096118B1 (en) 2005-12-01
AR048370A1 (es) 2006-04-26
EA200501666A1 (ru) 2006-06-30
TW200501948A (en) 2005-01-16
EP1620058B1 (en) 2012-01-04
DK1620058T3 (da) 2012-05-07
JP2012116859A (ja) 2012-06-21
US8859593B2 (en) 2014-10-14
WO2004096118A3 (en) 2005-10-13
JP4981440B2 (ja) 2012-07-18
SI1620058T1 (sl) 2012-05-31
EP1620058A2 (en) 2006-02-01
CL2004000877A1 (es) 2005-01-07
IL155666A0 (en) 2004-09-27
UY28296A1 (es) 2004-11-30
KR101136885B1 (ko) 2012-04-20
PT1620058E (pt) 2012-04-13
HK1087635A1 (en) 2006-10-20
IL155666A (en) 2013-12-31
IS8090A (is) 2005-10-25
NO333015B1 (no) 2013-02-18
KR20060005402A (ko) 2006-01-17
US20140378512A1 (en) 2014-12-25
UA87980C2 (ru) 2009-09-10
US20060229340A1 (en) 2006-10-12
NZ542724A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
ZA200509508B (en) Composition for improving cognition and memory
HK1079122A1 (en) Compositions and methods for combination antiviraltherapy
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
AU2003256805A8 (en) Compounds compositions and methods
GB0203421D0 (en) Composition
EP1684771A4 (en) COMPOSITION AND METHOD
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB0218241D0 (en) Composition
GB0229286D0 (en) Composition
GB0203528D0 (en) Process and composition
GB0213767D0 (en) Composition
GB0203616D0 (en) Composition
GB0303581D0 (en) Process and composition
GB0301401D0 (en) Composition and use
GB0311164D0 (en) Composition and use
GB0325238D0 (en) Composition and use
GB0311167D0 (en) Composition and use
GB0325241D0 (en) Composition and use
GB0311166D0 (en) Composition and use
GB0326699D0 (en) Method and composition
GB0225783D0 (en) Composition and process